Considering the limited data on the outcomes following CFTR modulator use during pregnancy and lactation, the MAYFLOWERS trial was initiated, which will examine the role of the continued use of modulators by comparing the pregnancy in women with CF who are modulator ineligible and in women with CF who choose to continue or discontinue CFTR modulator therapy during pregnancy and lactation (Jain et al., 2022b). Here, CFTR is linked to cystic fibrosis.